NCT05384119 2025-02-21Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast CancerTvardi Therapeutics, IncorporatedPhase 1 Terminated6 enrolled